| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endophthalmitis | 19 | 2017 | 262 | 2.900 |
Why?
|
| Eye Infections, Bacterial | 17 | 2023 | 238 | 2.020 |
Why?
|
| Free Tissue Flaps | 5 | 2018 | 335 | 1.610 |
Why?
|
| Surgical Wound Infection | 9 | 2021 | 1544 | 1.570 |
Why?
|
| Mycoses | 7 | 2017 | 389 | 1.440 |
Why?
|
| Keratitis | 5 | 2021 | 240 | 1.110 |
Why?
|
| Eye Infections | 3 | 2023 | 63 | 1.020 |
Why?
|
| Surgical Flaps | 4 | 2021 | 1678 | 1.000 |
Why?
|
| Eye Infections, Fungal | 8 | 2021 | 99 | 0.990 |
Why?
|
| Antibiotic Prophylaxis | 6 | 2016 | 641 | 0.980 |
Why?
|
| Prosthesis-Related Infections | 6 | 2016 | 497 | 0.930 |
Why?
|
| Bacterial Infections | 5 | 2017 | 1387 | 0.880 |
Why?
|
| Herpes Zoster Ophthalmicus | 3 | 2021 | 36 | 0.840 |
Why?
|
| Aspergillosis | 3 | 2021 | 242 | 0.840 |
Why?
|
| Head and Neck Neoplasms | 8 | 2021 | 2924 | 0.830 |
Why?
|
| Mucormycosis | 2 | 2021 | 104 | 0.810 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 2 | 2016 | 22 | 0.660 |
Why?
|
| Anti-Bacterial Agents | 24 | 2020 | 7473 | 0.660 |
Why?
|
| Sinusitis | 5 | 2021 | 995 | 0.640 |
Why?
|
| Eye Infections, Viral | 2 | 2016 | 58 | 0.600 |
Why?
|
| Vitrectomy | 9 | 2017 | 389 | 0.590 |
Why?
|
| Urinary Tract Infections | 2 | 2021 | 804 | 0.560 |
Why?
|
| Foscarnet | 1 | 2016 | 36 | 0.540 |
Why?
|
| Eye Infections, Parasitic | 3 | 2018 | 27 | 0.540 |
Why?
|
| Antifungal Agents | 7 | 2021 | 769 | 0.540 |
Why?
|
| Polymyxins | 1 | 2016 | 17 | 0.530 |
Why?
|
| Trimethoprim | 1 | 2016 | 79 | 0.520 |
Why?
|
| Cytosine | 1 | 2016 | 212 | 0.490 |
Why?
|
| Cornea | 5 | 2010 | 1315 | 0.470 |
Why?
|
| Histoplasma | 1 | 2014 | 40 | 0.470 |
Why?
|
| Bacteria | 6 | 2017 | 2210 | 0.470 |
Why?
|
| Clostridium Infections | 1 | 2021 | 563 | 0.460 |
Why?
|
| Bacteremia | 1 | 2021 | 988 | 0.460 |
Why?
|
| Histoplasmosis | 1 | 2014 | 63 | 0.460 |
Why?
|
| Vitreous Body | 6 | 2016 | 397 | 0.450 |
Why?
|
| Palatine Tonsil | 1 | 2014 | 193 | 0.450 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2015 | 354 | 0.440 |
Why?
|
| Eye | 2 | 2023 | 709 | 0.430 |
Why?
|
| Pharyngeal Diseases | 1 | 2014 | 134 | 0.430 |
Why?
|
| Syphilis | 4 | 2023 | 243 | 0.430 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2016 | 325 | 0.430 |
Why?
|
| Herpes Simplex | 1 | 2016 | 469 | 0.420 |
Why?
|
| Microsurgery | 1 | 2018 | 798 | 0.400 |
Why?
|
| Triazoles | 3 | 2021 | 898 | 0.370 |
Why?
|
| Orbital Cellulitis | 2 | 2009 | 33 | 0.370 |
Why?
|
| Laryngeal Diseases | 1 | 2014 | 248 | 0.370 |
Why?
|
| Toxocara | 1 | 2011 | 1 | 0.370 |
Why?
|
| Toxocariasis | 1 | 2011 | 12 | 0.370 |
Why?
|
| Antiparasitic Agents | 1 | 2011 | 41 | 0.360 |
Why?
|
| Clindamycin | 2 | 2016 | 138 | 0.350 |
Why?
|
| Eyelid Diseases | 3 | 2018 | 155 | 0.340 |
Why?
|
| Ethmoid Sinus | 1 | 2010 | 58 | 0.340 |
Why?
|
| Aqueous Humor | 2 | 2010 | 150 | 0.340 |
Why?
|
| Pneumonia | 1 | 2021 | 2158 | 0.330 |
Why?
|
| Vancomycin | 2 | 2011 | 504 | 0.330 |
Why?
|
| Corneal Ulcer | 4 | 2016 | 125 | 0.320 |
Why?
|
| Fusarium | 2 | 2007 | 50 | 0.310 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2010 | 107 | 0.310 |
Why?
|
| Artificial Organs | 1 | 2010 | 149 | 0.300 |
Why?
|
| Maxillary Sinus | 1 | 2010 | 172 | 0.300 |
Why?
|
| Abscess | 2 | 2010 | 605 | 0.300 |
Why?
|
| Prosthesis Implantation | 3 | 2009 | 594 | 0.290 |
Why?
|
| Dacryocystitis | 1 | 2008 | 68 | 0.290 |
Why?
|
| Lacrimal Apparatus | 1 | 2010 | 224 | 0.290 |
Why?
|
| Orbital Diseases | 4 | 2015 | 178 | 0.290 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2008 | 239 | 0.280 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2009 | 121 | 0.270 |
Why?
|
| Antiviral Agents | 3 | 2016 | 3053 | 0.270 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2021 | 704 | 0.260 |
Why?
|
| Contact Lenses | 2 | 2021 | 137 | 0.250 |
Why?
|
| Fungi | 3 | 2017 | 347 | 0.250 |
Why?
|
| Heart-Assist Devices | 1 | 2016 | 1297 | 0.240 |
Why?
|
| Herpesvirus 3, Human | 2 | 2016 | 157 | 0.240 |
Why?
|
| Aspergillus fumigatus | 1 | 2005 | 158 | 0.230 |
Why?
|
| Drug Therapy, Combination | 7 | 2007 | 6306 | 0.220 |
Why?
|
| Streptococcal Infections | 1 | 2008 | 616 | 0.220 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2004 | 79 | 0.220 |
Why?
|
| Staphylococcal Infections | 4 | 2016 | 1392 | 0.220 |
Why?
|
| Treponema pallidum | 1 | 2023 | 48 | 0.220 |
Why?
|
| Facial Paralysis | 2 | 2021 | 346 | 0.220 |
Why?
|
| Peptides, Cyclic | 1 | 2005 | 390 | 0.210 |
Why?
|
| Patient Readmission | 1 | 2017 | 3282 | 0.210 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2015 | 1065 | 0.210 |
Why?
|
| Gram-Positive Bacterial Infections | 3 | 2015 | 340 | 0.210 |
Why?
|
| Postoperative Complications | 8 | 2017 | 15802 | 0.210 |
Why?
|
| Retrospective Studies | 20 | 2021 | 81537 | 0.200 |
Why?
|
| Acanthamoeba Keratitis | 1 | 2021 | 14 | 0.190 |
Why?
|
| Streptococcus pyogenes | 1 | 2004 | 294 | 0.190 |
Why?
|
| Eye Evisceration | 2 | 2013 | 22 | 0.190 |
Why?
|
| Humans | 75 | 2023 | 765926 | 0.190 |
Why?
|
| Bell Palsy | 1 | 2021 | 39 | 0.190 |
Why?
|
| Achromobacter | 1 | 2021 | 8 | 0.190 |
Why?
|
| Keratitis, Herpetic | 1 | 2021 | 76 | 0.180 |
Why?
|
| Cataract Extraction | 4 | 2012 | 463 | 0.180 |
Why?
|
| Aged | 27 | 2023 | 171163 | 0.170 |
Why?
|
| Organ Preservation Solutions | 1 | 2021 | 105 | 0.170 |
Why?
|
| Drug Contamination | 1 | 2021 | 151 | 0.160 |
Why?
|
| Ophthalmic Solutions | 1 | 2021 | 312 | 0.160 |
Why?
|
| Limbus Corneae | 1 | 2021 | 144 | 0.160 |
Why?
|
| Massachusetts | 3 | 2017 | 8882 | 0.160 |
Why?
|
| Risk Factors | 14 | 2021 | 74850 | 0.160 |
Why?
|
| Middle Aged | 35 | 2023 | 223016 | 0.160 |
Why?
|
| Incidence | 8 | 2016 | 21513 | 0.150 |
Why?
|
| DNA, Bacterial | 1 | 2023 | 1476 | 0.150 |
Why?
|
| Simuliidae | 1 | 1998 | 5 | 0.150 |
Why?
|
| Onchocerciasis, Ocular | 1 | 1998 | 7 | 0.150 |
Why?
|
| Infusions, Intravenous | 2 | 2016 | 2227 | 0.150 |
Why?
|
| Catheter-Related Infections | 1 | 2021 | 279 | 0.150 |
Why?
|
| Myiasis | 1 | 2018 | 14 | 0.150 |
Why?
|
| Administration, Topical | 2 | 2016 | 702 | 0.150 |
Why?
|
| Onchocerca volvulus | 1 | 1998 | 14 | 0.150 |
Why?
|
| Diptera | 1 | 2018 | 50 | 0.150 |
Why?
|
| Glossectomy | 1 | 2018 | 60 | 0.150 |
Why?
|
| Combined Modality Therapy | 6 | 2016 | 8522 | 0.140 |
Why?
|
| Anti-Infective Agents | 3 | 2013 | 985 | 0.140 |
Why?
|
| Follow-Up Studies | 12 | 2018 | 39228 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 4 | 2023 | 6058 | 0.140 |
Why?
|
| Visual Acuity | 3 | 2009 | 2670 | 0.130 |
Why?
|
| Cutaneous Fistula | 1 | 2016 | 80 | 0.130 |
Why?
|
| Actinomycetaceae | 1 | 2015 | 5 | 0.130 |
Why?
|
| Nitriles | 1 | 2021 | 981 | 0.130 |
Why?
|
| Eye Enucleation | 2 | 2013 | 128 | 0.130 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2021 | 1970 | 0.130 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 185 | 0.130 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 2015 | 28 | 0.130 |
Why?
|
| Eyelids | 1 | 2018 | 278 | 0.120 |
Why?
|
| Risk Assessment | 3 | 2014 | 24275 | 0.120 |
Why?
|
| Eye Diseases | 3 | 2009 | 660 | 0.120 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 1996 | 72 | 0.120 |
Why?
|
| Paecilomyces | 1 | 2014 | 3 | 0.120 |
Why?
|
| Keratoplasty, Penetrating | 4 | 2021 | 143 | 0.120 |
Why?
|
| Conjunctivitis | 1 | 1996 | 153 | 0.120 |
Why?
|
| beta-Lactamases | 1 | 2016 | 308 | 0.120 |
Why?
|
| Otolaryngology | 1 | 2021 | 698 | 0.110 |
Why?
|
| Antibodies, Protozoan | 1 | 2015 | 250 | 0.110 |
Why?
|
| Toxoplasma | 1 | 2015 | 158 | 0.110 |
Why?
|
| Intravitreal Injections | 2 | 2015 | 391 | 0.110 |
Why?
|
| Corneal Diseases | 3 | 2010 | 535 | 0.110 |
Why?
|
| Oropharynx | 1 | 2014 | 139 | 0.110 |
Why?
|
| Optic Neuritis | 1 | 2016 | 172 | 0.110 |
Why?
|
| Male | 37 | 2023 | 363815 | 0.110 |
Why?
|
| Staphylococcus aureus | 2 | 2015 | 1422 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2005 | 3049 | 0.110 |
Why?
|
| Lymphopenia | 1 | 2015 | 298 | 0.110 |
Why?
|
| Rhinitis | 1 | 2020 | 752 | 0.100 |
Why?
|
| Pharyngitis | 1 | 2014 | 221 | 0.100 |
Why?
|
| Simplexvirus | 1 | 2016 | 804 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1613 | 0.100 |
Why?
|
| Device Removal | 1 | 2018 | 643 | 0.100 |
Why?
|
| Female | 30 | 2023 | 396141 | 0.100 |
Why?
|
| Stevens-Johnson Syndrome | 2 | 2009 | 231 | 0.100 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 519 | 0.100 |
Why?
|
| Diagnosis, Differential | 8 | 2016 | 12973 | 0.100 |
Why?
|
| Length of Stay | 2 | 2016 | 6486 | 0.100 |
Why?
|
| Wound Healing | 3 | 2018 | 2794 | 0.100 |
Why?
|
| Debridement | 3 | 2015 | 494 | 0.100 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2016 | 592 | 0.100 |
Why?
|
| Eye Burns | 2 | 2009 | 64 | 0.090 |
Why?
|
| Pythium | 1 | 2011 | 1 | 0.090 |
Why?
|
| Pythiosis | 1 | 2011 | 1 | 0.090 |
Why?
|
| Exanthema | 1 | 2016 | 503 | 0.090 |
Why?
|
| Young Adult | 11 | 2017 | 59857 | 0.090 |
Why?
|
| Bioprosthesis | 1 | 2016 | 592 | 0.090 |
Why?
|
| Sulfadiazine | 1 | 2010 | 18 | 0.090 |
Why?
|
| Aspergillus niger | 1 | 2010 | 18 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 4044 | 0.090 |
Why?
|
| Meningitis, Bacterial | 1 | 1993 | 222 | 0.090 |
Why?
|
| Virulence | 3 | 2016 | 1289 | 0.090 |
Why?
|
| Reoperation | 3 | 2018 | 4308 | 0.090 |
Why?
|
| Vancomycin Resistance | 1 | 2011 | 125 | 0.090 |
Why?
|
| Adult | 24 | 2023 | 223088 | 0.090 |
Why?
|
| Bacterial Typing Techniques | 2 | 2023 | 263 | 0.090 |
Why?
|
| Retropharyngeal Abscess | 1 | 2010 | 21 | 0.080 |
Why?
|
| Gram-Positive Cocci | 1 | 2009 | 8 | 0.080 |
Why?
|
| Eye Injuries | 1 | 2013 | 228 | 0.080 |
Why?
|
| Virus Diseases | 1 | 1996 | 718 | 0.080 |
Why?
|
| Pyridines | 1 | 2021 | 2885 | 0.080 |
Why?
|
| Haemophilus paraphrophilus | 1 | 2008 | 1 | 0.080 |
Why?
|
| Aneurysm, Infected | 1 | 2009 | 82 | 0.080 |
Why?
|
| Eikenella corrodens | 1 | 2008 | 17 | 0.080 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2009 | 113 | 0.080 |
Why?
|
| Crowns | 1 | 2009 | 156 | 0.080 |
Why?
|
| Streptococcus anginosus | 1 | 2008 | 25 | 0.080 |
Why?
|
| Addison Disease | 1 | 2009 | 48 | 0.080 |
Why?
|
| Chronic Disease | 5 | 2020 | 9351 | 0.080 |
Why?
|
| Chemoprevention | 1 | 2011 | 327 | 0.080 |
Why?
|
| Treatment Outcome | 9 | 2020 | 65194 | 0.070 |
Why?
|
| Streptococcus agalactiae | 1 | 2009 | 328 | 0.070 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 59496 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 865 | 0.070 |
Why?
|
| Hearing Loss, Sudden | 1 | 2008 | 44 | 0.070 |
Why?
|
| Temporal Arteries | 1 | 2008 | 155 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2016 | 1319 | 0.070 |
Why?
|
| Alternaria | 1 | 2007 | 41 | 0.070 |
Why?
|
| Carotid Artery, Internal | 1 | 2009 | 440 | 0.070 |
Why?
|
| Dura Mater | 1 | 2008 | 295 | 0.070 |
Why?
|
| Prostheses and Implants | 2 | 2005 | 1273 | 0.070 |
Why?
|
| Focal Infection, Dental | 1 | 2006 | 27 | 0.070 |
Why?
|
| Drainage | 2 | 2010 | 1181 | 0.060 |
Why?
|
| Candida | 1 | 2007 | 174 | 0.060 |
Why?
|
| Orbit Evisceration | 1 | 2005 | 9 | 0.060 |
Why?
|
| Corneal Transplantation | 1 | 2009 | 315 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6503 | 0.060 |
Why?
|
| Leishmaniasis, Mucocutaneous | 1 | 2005 | 14 | 0.060 |
Why?
|
| Leishmania braziliensis | 1 | 2005 | 16 | 0.060 |
Why?
|
| Echinocandins | 1 | 2005 | 57 | 0.060 |
Why?
|
| Lipopeptides | 1 | 2005 | 73 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 2170 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2015 | 2234 | 0.060 |
Why?
|
| Granuloma, Pyogenic | 1 | 2005 | 47 | 0.060 |
Why?
|
| Meningitis, Meningococcal | 1 | 2004 | 43 | 0.060 |
Why?
|
| Glucocorticoids | 3 | 2009 | 2155 | 0.060 |
Why?
|
| Keratoconjunctivitis | 1 | 2004 | 41 | 0.060 |
Why?
|
| Biopsy | 2 | 2014 | 6766 | 0.060 |
Why?
|
| Giant Cell Arteritis | 1 | 2008 | 308 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2016 | 4210 | 0.060 |
Why?
|
| Neisseria meningitidis | 1 | 2004 | 111 | 0.060 |
Why?
|
| Cellulitis | 1 | 2006 | 206 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 11030 | 0.060 |
Why?
|
| Intraocular Pressure | 1 | 2010 | 1302 | 0.050 |
Why?
|
| Cross Infection | 1 | 1993 | 1426 | 0.050 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2005 | 192 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 4555 | 0.050 |
Why?
|
| Cicatrix | 1 | 2009 | 796 | 0.050 |
Why?
|
| Molecular Typing | 1 | 2023 | 115 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 4405 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 2729 | 0.050 |
Why?
|
| Time Factors | 3 | 2016 | 40097 | 0.050 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2023 | 765 | 0.050 |
Why?
|
| Uveitis | 2 | 2016 | 391 | 0.050 |
Why?
|
| Carotid Stenosis | 1 | 2009 | 857 | 0.050 |
Why?
|
| Immunoconjugates | 1 | 2010 | 976 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2008 | 781 | 0.050 |
Why?
|
| Equipment Design | 1 | 2009 | 3490 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3928 | 0.050 |
Why?
|
| Encephalomyelitis, Eastern Equine | 1 | 2001 | 14 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2009 | 1962 | 0.050 |
Why?
|
| Adolescent | 8 | 2015 | 88811 | 0.050 |
Why?
|
| Eye Banks | 1 | 2021 | 40 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 2012 | 4213 | 0.040 |
Why?
|
| Diabetic Foot | 1 | 2004 | 383 | 0.040 |
Why?
|
| Candida albicans | 2 | 2001 | 377 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2010 | 20690 | 0.040 |
Why?
|
| Glaucoma | 1 | 2010 | 1192 | 0.040 |
Why?
|
| DNA, Ribosomal | 1 | 2021 | 300 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2021 | 276 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 1555 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2017 | 41680 | 0.040 |
Why?
|
| Prevalence | 2 | 2011 | 15828 | 0.040 |
Why?
|
| Vision, Monocular | 1 | 1999 | 71 | 0.040 |
Why?
|
| Mycobacterium Infections | 1 | 1999 | 122 | 0.040 |
Why?
|
| Candidiasis | 1 | 2001 | 372 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 3079 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2021 | 373 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2023 | 4780 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 1997 | 152 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2015 | 2586 | 0.030 |
Why?
|
| Anterior Eye Segment | 1 | 1998 | 144 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 1042 | 0.030 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2016 | 37 | 0.030 |
Why?
|
| Latin America | 1 | 1998 | 416 | 0.030 |
Why?
|
| Vision Disorders | 2 | 2016 | 1085 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2001 | 667 | 0.030 |
Why?
|
| HIV Infections | 3 | 2016 | 17531 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2009 | 4503 | 0.030 |
Why?
|
| Neurosyphilis | 1 | 2016 | 27 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2014 | 4016 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 1998 | 302 | 0.030 |
Why?
|
| Chorioretinitis | 1 | 2015 | 43 | 0.030 |
Why?
|
| Anterior Chamber | 2 | 2011 | 194 | 0.030 |
Why?
|
| Africa | 1 | 1998 | 725 | 0.030 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2016 | 50 | 0.030 |
Why?
|
| Mucorales | 1 | 2015 | 35 | 0.030 |
Why?
|
| Aspergillus | 1 | 2015 | 93 | 0.030 |
Why?
|
| Child | 6 | 2021 | 80568 | 0.030 |
Why?
|
| Acyclovir | 1 | 2015 | 266 | 0.030 |
Why?
|
| Lenses, Intraocular | 1 | 1996 | 141 | 0.030 |
Why?
|
| HIV Seronegativity | 1 | 2015 | 209 | 0.030 |
Why?
|
| Argentina | 1 | 2015 | 249 | 0.030 |
Why?
|
| New Zealand | 1 | 2015 | 359 | 0.030 |
Why?
|
| Tissue Donors | 2 | 2021 | 2392 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2010 | 3743 | 0.030 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2015 | 167 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2016 | 583 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 663 | 0.030 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2016 | 245 | 0.030 |
Why?
|
| Valine | 1 | 2015 | 410 | 0.030 |
Why?
|
| Arthritis, Psoriatic | 1 | 2016 | 218 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1996 | 832 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 851 | 0.030 |
Why?
|
| HIV-1 | 1 | 2010 | 6945 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 5752 | 0.020 |
Why?
|
| Neuromyelitis Optica | 1 | 2016 | 266 | 0.020 |
Why?
|
| Suppuration | 1 | 2011 | 60 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15401 | 0.020 |
Why?
|
| Fever | 2 | 2009 | 1607 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2016 | 1517 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2010 | 42510 | 0.020 |
Why?
|
| Endoscopy | 1 | 2020 | 1854 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2015 | 1186 | 0.020 |
Why?
|
| Uveitis, Posterior | 1 | 2010 | 45 | 0.020 |
Why?
|
| Cardiolipins | 1 | 2010 | 82 | 0.020 |
Why?
|
| United States | 3 | 2016 | 72909 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 15878 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 2016 | 533 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2015 | 1047 | 0.020 |
Why?
|
| Canada | 1 | 2015 | 2120 | 0.020 |
Why?
|
| Internationality | 1 | 2015 | 1007 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2015 | 2915 | 0.020 |
Why?
|
| Recurrence | 2 | 2011 | 8492 | 0.020 |
Why?
|
| Dehydration | 1 | 2010 | 215 | 0.020 |
Why?
|
| Fundus Oculi | 1 | 2010 | 542 | 0.020 |
Why?
|
| Genotype | 1 | 2023 | 13026 | 0.020 |
Why?
|
| Polyuria | 1 | 2008 | 37 | 0.020 |
Why?
|
| Hearing Loss | 1 | 2016 | 785 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2010 | 403 | 0.020 |
Why?
|
| Ophthalmology | 1 | 2015 | 559 | 0.020 |
Why?
|
| India | 1 | 2015 | 2334 | 0.020 |
Why?
|
| Israel | 1 | 2011 | 729 | 0.020 |
Why?
|
| Animals | 4 | 2018 | 168735 | 0.020 |
Why?
|
| Urinalysis | 1 | 2010 | 369 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3801 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 1993 | 527 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2015 | 2426 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2010 | 540 | 0.020 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2008 | 210 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 14643 | 0.020 |
Why?
|
| Steroids | 1 | 2012 | 934 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2013 | 1475 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2008 | 284 | 0.020 |
Why?
|
| Infant | 1 | 2009 | 36426 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2000 | 5987 | 0.020 |
Why?
|
| Saphenous Vein | 1 | 2009 | 519 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2010 | 1605 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2008 | 369 | 0.020 |
Why?
|
| Cochlear Nerve | 1 | 2008 | 202 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 6321 | 0.020 |
Why?
|
| Nafcillin | 1 | 2005 | 23 | 0.020 |
Why?
|
| Antimony Sodium Gluconate | 1 | 2005 | 10 | 0.020 |
Why?
|
| Boston | 2 | 2001 | 9334 | 0.020 |
Why?
|
| Trypanocidal Agents | 1 | 2005 | 40 | 0.010 |
Why?
|
| Polymethyl Methacrylate | 1 | 2005 | 127 | 0.010 |
Why?
|
| Burns, Chemical | 1 | 2005 | 123 | 0.010 |
Why?
|
| Nose Diseases | 1 | 2005 | 78 | 0.010 |
Why?
|
| Conjunctival Neoplasms | 1 | 2005 | 78 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2008 | 551 | 0.010 |
Why?
|
| Prednisone | 1 | 2008 | 1566 | 0.010 |
Why?
|
| Bone Cements | 1 | 2005 | 319 | 0.010 |
Why?
|
| Ceftriaxone | 1 | 2004 | 176 | 0.010 |
Why?
|
| Hospital Mortality | 2 | 1997 | 5339 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2015 | 9656 | 0.010 |
Why?
|
| Nasal Obstruction | 1 | 2005 | 162 | 0.010 |
Why?
|
| Injections | 1 | 2005 | 839 | 0.010 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 2876 | 0.010 |
Why?
|
| Acute Disease | 1 | 1993 | 7236 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2010 | 2866 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 1899 | 0.010 |
Why?
|
| Pain | 2 | 2009 | 5077 | 0.010 |
Why?
|
| Penicillins | 1 | 2004 | 403 | 0.010 |
Why?
|
| Cholesterol | 1 | 2010 | 2902 | 0.010 |
Why?
|
| Nose | 1 | 2005 | 518 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2015 | 54807 | 0.010 |
Why?
|
| Amphotericin B | 1 | 2001 | 140 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 1506 | 0.010 |
Why?
|
| Headache | 1 | 2008 | 1261 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1996 | 8037 | 0.010 |
Why?
|
| Gram-Positive Bacteria | 1 | 2001 | 179 | 0.010 |
Why?
|
| Seizures | 1 | 1993 | 2997 | 0.010 |
Why?
|
| Amikacin | 1 | 1999 | 48 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 13463 | 0.010 |
Why?
|
| Asthma | 1 | 1997 | 6268 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2012 | 8724 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2008 | 36547 | 0.010 |
Why?
|
| Acute Kidney Injury | 1 | 2010 | 1943 | 0.010 |
Why?
|
| Status Asthmaticus | 1 | 1997 | 21 | 0.010 |
Why?
|
| Sympathomimetics | 1 | 1997 | 56 | 0.010 |
Why?
|
| Radiography | 1 | 2008 | 6941 | 0.010 |
Why?
|
| Azithromycin | 1 | 1999 | 202 | 0.010 |
Why?
|
| Mycobacterium | 1 | 1999 | 252 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 3599 | 0.010 |
Why?
|
| France | 1 | 1997 | 495 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1997 | 345 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 29890 | 0.010 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2008 | 1898 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 26282 | 0.010 |
Why?
|
| Disease Progression | 1 | 2011 | 13614 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 3684 | 0.010 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1997 | 572 | 0.010 |
Why?
|
| Dyspnea | 1 | 1997 | 1351 | 0.010 |
Why?
|
| Forecasting | 1 | 1997 | 2936 | 0.000 |
Why?
|
| Brain | 2 | 2008 | 27179 | 0.000 |
Why?
|
| Cause of Death | 1 | 1997 | 3715 | 0.000 |
Why?
|
| Melanoma | 1 | 2005 | 5695 | 0.000 |
Why?
|
| Critical Care | 1 | 1997 | 2713 | 0.000 |
Why?
|
| Survival Rate | 1 | 1997 | 12822 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 1997 | 12529 | 0.000 |
Why?
|
| Age Factors | 1 | 1997 | 18382 | 0.000 |
Why?
|
| Hospitalization | 1 | 1997 | 10810 | 0.000 |
Why?
|